RedHill Biopharma (NASDAQ:RDHL) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research report sent to investors on Saturday. The firm issued a hold rating on the biotechnology company’s stock.

RedHill Biopharma Stock Down 4.7 %

NASDAQ:RDHL opened at $2.66 on Friday. RedHill Biopharma has a 12 month low of $2.47 and a 12 month high of $20.28. The company has a 50-day moving average price of $4.37 and a 200-day moving average price of $6.51.

Institutional Investors Weigh In On RedHill Biopharma

A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC purchased a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma at the end of the most recent reporting period. 7.20% of the stock is currently owned by institutional investors and hedge funds.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.